Cargando…

Systemic Immunomodulatory Effects of Combinatorial Treatment of Thalidomide and Dexamethasone on T Cells and Other Immune Cells

PURPOSE: In organ transplantation, the need for immune modulation rather than immune suppression has been emphasized. In this study, we investigated whether combinatorial treatments of with thalidomide (TM) and dexamethasone (DX) might be new approaches to induce systemic immunomodulation on T cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Eun Jee, Kim, Joon Ye, Choi, Hoon Young, Lee, Hyojung, Lee, Juhan, Kim, Myoung Soo, Kim, Yu Seun, Huh, Kyu Ha, Kim, Beom Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859687/ https://www.ncbi.nlm.nih.gov/pubmed/33527793 http://dx.doi.org/10.3349/ymj.2021.62.2.137

Ejemplares similares

The Immunomodulating Effects of Thalidomide and Dexamethasone in a Murine Cardiac Allograft Transplantation Model
por: Kim, Soo Jin, et al.
Publicado: (2022)

Early hospital readmissions after ABO- or HLA- incompatible living donor kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2019)

Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2018)

Clinical significance of tacrolimus intra-patient variability on kidney transplant outcomes according to pre-transplant immunological risk
por: Kim, Eun Jin, et al.
Publicado: (2021)

Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: a propensity-matched study
por: Kim, Deok Gie, et al.
Publicado: (2019)

Clinical impact of serum bilirubin levels on kidney transplant outcomes
por: Lee, Juhan, et al.
Publicado: (2021)

Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study
por: Kim, Deok Gie, et al.
Publicado: (2019)

A 12-Month Single Arm Pilot Study to Evaluate the Efficacy and Safety of Sirolimus in Combination with Tacrolimus in Kidney Transplant Recipients at High Immunologic Risk
por: Lee, Juhan, et al.
Publicado: (2015)

The recovery status from delayed graft function can predict long-term outcome after deceased donor kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2017)

The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
por: Lee, Juhan, et al.
Publicado: (2015)

Reduced expression of pyruvate kinase in kidney proximal tubule cells is a potential mechanism of pravastatin altered glucose metabolism
por: Lee, Yong Pyo, et al.
Publicado: (2019)

The feasibility of organ transplantation during the COVID-19 outbreak: experiences from South Korea
por: Lee, Juhan, et al.
Publicado: (2020)

Long-term compensation of renal function after donor nephrectomy
por: Lee, Yong Pyo, et al.
Publicado: (2020)

Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients
por: Kim, Hyung Woo, et al.
Publicado: (2023)

Variability of the Estimated Glomerular Filtration Rate in the First Year after Kidney Transplantation Is an Independent Risk Factor for Poor Renal Allograft Outcomes: A Retrospective Cohort Study
por: Choi, Hoon Young, et al.
Publicado: (2016)

Risk factors for Pneumocystis jirovecii pneumonia (PJP) in kidney transplantation recipients
por: Lee, Su Hwan, et al.
Publicado: (2017)

Successful kidney transplantation across a positive complement-dependent cytotoxicity crossmatch by using C1q assay-directed, bortezomib-assisted desensitization: A case report
por: Lee, Juhan, et al.
Publicado: (2017)

Association between post-transplant serum uric acid levels and kidney transplantation outcomes
por: Kim, Deok Gie, et al.
Publicado: (2018)

Association between post-transplant uric acid level and renal allograft fibrosis: Analysis using Banff pathologic scores from renal biopsies
por: Kim, Deok Gie, et al.
Publicado: (2018)

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
por: Lee, Yoo Jin, et al.
Publicado: (2019)

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
por: Hus, Marek, et al.
Publicado: (2011)

Graft-versus-host disease after simultaneous pancreas-kidney transplantation
por: Lee, Juhan, et al.
Publicado: (2020)

Role of Plasma Exchange in ABO-incompatible Kidney Transplantation
por: Yoo, Soohun, et al.
Publicado: (2012)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

The first robotic kidney transplantation in Korea: a case report
por: Kim, Hyun Jeong, et al.
Publicado: (2022)

Successful kidney transplantation after desensitization in a patient with positive flow crossmatching and donor-specific anti-HLA-DP antibody: A Case report
por: Song, Seung Hwan, et al.
Publicado: (2016)

Thalidomide Inhibits Alternative Activation of Macrophages In Vivo and In Vitro: A Potential Mechanism of Anti-Asthmatic Effect of Thalidomide
por: Lee, Hyun Seung, et al.
Publicado: (2015)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Immunomodulatory effects of thalidomide in an experimental brain death liver donor model
por: Santana, Alexandre Chagas, et al.
Publicado: (2021)

Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study
por: Kang, Ji-Man, et al.
Publicado: (2023)

Kidney transplantation trends in South Korea during the COVID-19 pandemic
por: Lee, Juhan, et al.
Publicado: (2020)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group
por: Song, Young Hae, et al.
Publicado: (2012)

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
por: Dredge, K, et al.
Publicado: (2002)

Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study
por: Giamarellos-Bourboulis, Evangelos J, et al.
Publicado: (2005)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Clinical significance of donor-specific anti-HLA-DR51/52/53 antibodies for antibody-mediated rejection in kidney transplant recipients
por: Park, Borae Geum, et al.
Publicado: (2019)

Antiallodynic Effect of Thalidomide and Morphine on Rat Spinal Nerve Ligation-induced Neuropathic Pain
por: Choi, Jeong Il, et al.
Publicado: (2010)

Survival Benefit of Kidney Transplantation in Patients With End-Stage Kidney Disease and Prior Acute Myocardial Infarction
por: Kim, Deok-Gie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qdet08d5737eptdaaajrvss734